Similarly, our results showed that Ellorarxine can significantly reduce LPS-induced IL-6 expression in Wild type SOD1 and Mutant SOD1 NSC-34 cells, which is not only consistent with previous reports of other synthetic retinoids, but also suggests that Ellorarxine may be able to successfully reduce the chronic inflammatory response observed in ALS. The gene discussed is IL6; the disease is amyotrophic lateral sclerosis.